Status:
COMPLETED
Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
Bristol-Myers Squibb
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study is being carried out to see if dapagliflozin in addition to glimepiride (sulphonylurea) is effective and safe in treating patients with type 2 diabetes when compared to glimepiride alone.
Eligibility Criteria
Inclusion
- Type 2 Diabetes
- Treatment with a stable sulphonylurea monotherapy dose that is at least half the maximal recommended dose for a minimum of 8 weeks prior to study
- Inadequate glycaemic control, defined as A1C ≥ 7.0 % and ≤ 10%
Exclusion
- Type 1 Diabetes
- Hepatic (liver) impairment
- Renal (kidney) failure or dysfunction
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2010
Estimated Enrollment :
597 Patients enrolled
Trial Details
Trial ID
NCT00680745
Start Date
April 1 2008
End Date
May 1 2010
Last Update
October 14 2013
Active Locations (66)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Blansko, Czechia
2
Research Site
Bruntál, Czechia
3
Research Site
Břeclav, Czechia
4
Research Site
Hodonín, Czechia